|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrastenhanced endoscopic ultrasonography显示文摘AIM: To elucidate the role of contrast-enhanced endoscopic ultrasonography(CE-EUS) in the diagnosis of branch duct intraductal papillary mucinous neoplasm(BD-IPMN).METHODS: A total of 50 patients diagnosed with BDIPMN by computed tomography(CT) and endoscopic ultrasonography(EUS) at our institute were included in this study. CE-EUS was performed when mural lesions were detected by EUS. The diagnostic accuracy for identifying mural nodules(MNs) was evaluated by CT, EUS, and EUS combined with CE-EUS. In the patients who underwent resection, the accuracy of measuring MN height with each imaging modality was compared. The cut-off values to diagnose malignant BD-IPMNs based on MN height for each imaging modality were determined using receiver operating characteristic curve analysis.RESULTS: Fifteen patients were diagnosed with BD-IPMN with MNs and underwent resection. The remaining 35 patients were diagnosed with BD-IPMN without MNs and underwent follow-up monitoring. The pathological findings revealed 14 cases with MNs and one case without. The accuracy for diagnosing MNs was 92% using CT and 72% using EUS; the diagnostic accuracy increased to 98% when EUS and CE-EUS were combined. The accuracy for measuring MN height significantly improved when using CE-EUS compared with using CT or EUS(median measurement error value, CT: 3.3 mm vs CE-EUS: 0.6 mm, P < 0.05; EUS: 2.1 mm vs CE-EUS: 0.6 mm, P < 0.01). A cut-off value of 8.8 mm for MN height as measured by CE-EUS improved the accuracy of diagnosing malignant BDIPMN to 93%. CONCLUSION: Using CE-EUS to measure MN height provides a highly accurate method for differentiating benign from malignant BD-IPMN. | Hirofumi Harima Seiji Kaino Shuhei Shinoda Michitaka Kawano Shigeyuki Suenaga Isao Sakaida | 2015 | World Journal of Gastroenterology2015，21，20： | 12 |
| 2 | Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy显示文摘Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials. | Issei Saeki Takahiro Yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto Yutaka Suehiro Taro Takami Isao Sakaida | 2018 | World Journal of Hepatology2018，10，9： | 10 |
| 3 | Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function显示文摘Hepatocellular carcinoma(HCC) is one of the deadliest cancers in the world and is associated with a high risk of recurrence. The development of a wide range of new therapies is therefore essential. In this study, from the perspective of supportive therapy for the prevention of HCC recurrence and preservation of liver function in HCC patients, we surveyed a variety of different therapeutic agents. We show that branched chain amino acids(BCAA) supplementation and late evening snack with BCAA, strategies that address issues of protein-energy malnutrition, are important for liver cirrhotic patients with HCC. For chemoprevention of HCC recurrence, we show that viral control after radical treatment is important. We also reviewed the therapeutic potential of antiviral drugs, sorafenib, peretinoin, iron chelators. Sorafenib is a kinase inhibitor and a standard therapy in the treatment of advanced HCC. Peretinoin is a vitamin A-like molecule that targets the retinoid nuclear receptor to induce apoptosis and inhibit tumor growth in HCC cells. Iron chelators, such as deferoxamine and deferasirox, act to prevent cancer cell growth. These chelators may have potential as combination therapies in conjunction with peretinoin. Finally, we review the potential inhibitory effect of bone marrow cells on hepatocarcinogenesis. | Taro Takami Takahiro Yamasaki Issei Saeki Toshihiko Matsumoto Yutaka Suehiro Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，32： | 4 |
| 4 | Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow显示文摘 | Haruko Tanimoto Shuji Terai Takami Taro Yasuhiko Murata Kouichi Fujisawa Naoki Yamamoto Isao Sakaida | 2013 | Cell and Tissue Research2013，，3： | 3 |
| 5 | Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma显示文摘AIM To evaluate the inhibitory effects of deferasirox(DFX) against hepatocellular carcinoma(HCC) through basic and clinical studies.METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines(Hep G2, Hep3 B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity(according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was reduced.RESULTS Administration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors(P < 0.01), and significantly upregulated the mR NA expression levels of hepcidin(P < 0.05), transferrin receptor 1(P < 0.05), and hypoxia inducible factor-1α(P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSION We demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities. | Issei Saeki Naoki Yamamoto Takahiro Yamasaki Taro Takami Masaki Maeda Koichi Fujisawa Takuya Iwamoto Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Koichi Uchida Kenji Tani Isao Sakaida | 2016 | World Journal of Gastroenterology2016，22，40： | 3 |
| 6 | Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice显示文摘 | Takuya Iwamoto Shuji Terai Takuro Hisanaga Taro Takami Naoki Yamamoto Shoko Watanabe Isao Sakaida | 2013 | Cell and Tissue Research2013，，3： | 2 |
| 7 | Hepatocellular carcinoma with nonalcoholic steatohepatitis显示文摘 | Sayaka Mori Takahiro Yamasaki Isao Sakaida Taro Takami Eiki Sakaguchi Teruaki Kimura Fumie Kurokawa Shiro Maeyama Kiwamu Okita | 2004 | Journal of Gastroenterology2004，，4： | 2 |
| 8 | Identification of genes specifically methylated in E pstein– B arr virus‐associated gastric carcinomas显示文摘 | Toshiyuki Okada Munetaka Nakamura Jun Nishikawa Kouhei Sakai Yibo Zhang Mari Saito Akihiro Morishige Atsunori Oga Kosuke Sasaki Yutaka Suehiro Yuji Hinoda Isao Sakaida | 2013 | Cancer Sci2013，，10： | 2 |
| 9 | Stem cell therapy in chronic liver disease显示文摘 | Taro Takami Shuji Terai Isao Sakaida | 2012 | Current Opinion in Gastroenterology2012，，3： | 2 |
| 10 | Gadolinium chloride reverses dimethylnitrosamine (DMN)-induced rat liver fibrosis with increased matrix metalloproteinases (MMPs) of Kupffer cells显示文摘 | Hironaka K Terai S | 2003 | Life Sci2003，72，8： | 1 |
| 11 | Cytoprotection by glycine against hypoxia-induced injury in cultured hepatocytes显示文摘 | Nagatomi A Sakaida I Matsumura Y | 1997 | Liver1997，17，2： | 1 |
| 12 | Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet 显示文摘 | KAWAGUCHI K SAKAIDA I TSUCHIYA M | 2004 | Biochem Biophys Res Commun2004，315，1： | 1 |
| 13 | Endovascular management of vertebral artery dissecting aneurysms: review of 25 patients 显示文摘 | Taha MM Sakaida It Asakura F | 2010 | Turk Neurosurg2010，20，2： | 1 |
| 14 | Ubiquitin is a possible new predictive marker for the recurrence of human hepatocellular carcinoma显示文摘 | Shirahashi H Sakaida I Terai S | 2002 | Liver2002，22，5： | 1 |
| 15 | Spl and p73 activate PUMA following serum starvation 显示文摘 | Ming L Sakaida T Yue W | 2008 | Carcinogenesis2008，29，10： | 1 |
| 16 | Fibrosis accelerates the development of enzyme- altered lesions in the rat liver显示文摘 | Sakaida I Hironaka K Uchida K | 1998 | He Patology1998，28，5： | 1 |
| 17 | Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell显示文摘 | Hironaka K Kimura T | 2004 | Life Sci2004，74，18： | 1 |
| 18 | Pioglitazone prevents hepatic steatosisfibrosis, and enzyme- altered lesions in rat liver cirrhosis induced by a choline - deficient L - amino acid-defined diet显示文摘 | Kawaguchi K Sakaida I Tsuchiya M | 2004 | Biochem Biophys Res Commun2004，315，1： | 1 |
| 19 | Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double‐blind, placebo‐controlled trial显示文摘 | Isao Sakaida Seiji Kawazoe Kozo Kajimura Takafumi Saito Chiaki Okuse Koichi Takaguchi Mitsuru Okada Kiwamu Okita | 2014 | Hepatol Res2014，，1： | 1 |
| 20 | Magnetic and Mechanical Properties of High Strength Non-oriented Electrical Steel显示文摘 | Tachino I Kubota T Sakaida A | 1990 | Anales de Fisica B1990，86，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员